Study of Glipizide to Understand Insulin Secretion and KATP Channel Role in Type 2 Diabetes Progression in Adults

What this Trial Is About

This research investigates the role of ATP-sensitive potassium KATP channels in insulin secretion and their connection to type 2 diabetes T2D. The study explores how loss of KATP channel activity in pancreatic beta cells may lead to the progression from excessive insulin release to reduced secretion, a pattern seen in T2D. Researchers aim to understand whether this loss contributes to poor blood sugar control in people with and without T2D. Participants will ingest a single 10 mg dose of glipizide, a sulfonylurea drug that inhibits KATP channels. The study includes four groups lean individuals with normal glucose tolerance, obese individuals with normal glucose tolerance, obese individuals with impaired fasting glucose, and obese individuals with type 2 diabetes. The goal is to observe insulin responses after glipizide ingestion to assess KATP channel activity among these groups. During the study, participants will be monitored for insulin secretion 90 minutes after taking glipizide. Various health measurements including body mass index, fasting plasma glucose, oral glucose tolerance, and hemoglobin A1C levels will be used to classify participants. The researchers will track changes in insulin secretion to better understand beta cell function related to KATP channels in relation to diabetes progression. The study is expected to complete by March 2027.

Role of KATP Channel Loss in Type 2 Diabetes